A randomised phase III cross-over study of tamoxifen versus megestrol acetate in advanced and recurrent breast cancer

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
N S StuartH Earl

Abstract

139 peri- and postmenopausal women with advanced or recurrent breast cancer who had not received prior hormonal therapy were randomised in an open, cross-over study comparing the synthetic progestogen megestrol acetate with tamoxifen. The response rate (CR/PR) to megestrol acetate (25%; 95% confidence interval (CI) 15-35%) was not significantly different from that produced by tamoxifen (33%, CI 22-44%). Time-to-treatment failure was also similar in the two groups. Cross-over treatment was given on progression in 76 cases. Cross-over response (CR/PR) was seen in 3 of 35 patients (9%) receiving megestrol acetate as second-line therapy and in 6 of 41 patients (15%) receiving tamoxifen second-line. There was no significant difference in survival between the groups (P = 0.17) with median survival times of 24 and 32 months for the megestrol acetate and tamoxifen groups, respectively. The toxicity profile of the two drugs was different, although significant toxicity was rare with either agent. Megestrol acetate is an effective treatment for advanced breast cancer in older women when used either as first- or second-line treatment. Cross-over response is seen following both treatments. Given that most patients now receive tamoxifen as a...Continue Reading

References

Jan 1, 1992·Acta Oncologica·S Lundgren
Mar 1, 1990·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P H WillemseH van Veelen
Jan 1, 1988·Acta Oncologica·C Rose, H T Mouridsen
Aug 7, 2013·Hematology/oncology Clinics of North America·Gaia Schiavon, Ian E Smith

❮ Previous
Next ❯

Citations

Mar 3, 2007·Breast Cancer Research and Treatment·Henning T Mouridsen
Jul 16, 2002·Clinical Therapeutics·Leroy Monroe Parker
Jun 18, 2002·Journal of Pain and Symptom Management·Patricia F HarrisPolly A Newcomb
Oct 1, 1998·The New England Journal of Medicine·G N Hortobagyi
Jun 17, 2004·Molecular and Cellular Biology·Mahnaz RazandiEllis R Levin
Apr 14, 2006·Journal of Endocrinological Investigation·A R ChidakelA M Fleckman
Dec 18, 2013·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Fan LiYi Xiang
Feb 19, 2011·Critical Reviews in Oncology/hematology·Nagi S El SaghirAhmad Awada
Apr 15, 2006·Expert Review of Anticancer Therapy·Ruth E BoardAndrew M Wardley
Jul 13, 2002·Expert Review of Anticancer Therapy·Paul E Goss, Robert E Smith
Sep 8, 2000·Molecular Endocrinology·M RazandiE R Levin
Nov 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M NabholtzM von Euler
May 19, 2006·PharmacoEconomics·Christopher Dunn, Susan J Keam

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
W JonatM Azab
© 2021 Meta ULC. All rights reserved